Marek W Radomski
Overview
Explore the profile of Marek W Radomski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krason M, Paradowska A, Boncel S, Lejawa M, Fronczek M, Sliwka J, et al.
ACS Omega
. 2024 Jul;
9(26):28397-28411.
PMID: 38973833
Interactions of graphene oxide (GO) with an rat heart and its coronary vessels have not been studied yet. Moreover, the conflicting data on the "structure-properties" relationships do not allow for...
2.
Krason M, Paradowska A, Fronczek M, Lejawa M, Kamienska N, Krejca M, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896255
Methods: Four types of GO commercially available aqueous dispersions (with different particle structures) were diluted, sonicated and studied in the presence of BSA and physiological cation concentrations. Nanoparticle populations sizes,...
3.
Taterra D, Skinningsrud B, Pekala P, Tomaszewska I, Marycz K, Radomski M, et al.
Nanotoxicology
. 2020 Nov;
15(1):52-65.
PMID: 33147415
Nanoparticles (NPs) are released from orthopedic and neurosurgical prostheses and can interact with a number of blood components once in the bloodstream. Potential toxic effects of Co and Cr NPs...
4.
OSullivan S, Wang J, Radomski M, Gilmer J, Medina C
Biomolecules
. 2020 May;
10(5).
PMID: 32466182
Matrix metalloproteinase-9 is upregulated in inflammatory bowel disease. Barbiturate nitrate hybrid compounds have been designed to inhibit MMP secretion and enzyme activity. In this study, we investigated the mechanism of...
5.
Inkielewicz-Stepniak I, Tajber L, Behan G, Zhang H, Radomski M, Medina C, et al.
Materials (Basel)
. 2018 May;
11(5).
PMID: 29751544
The development of novel oral drug delivery systems is an expanding area of research and both new approaches for improving their efficacy and the investigation of their potential toxicological effect...
6.
Larkin C, Hante N, Breen E, Tomaszewski K, Eisele S, Radomski M, et al.
PLoS One
. 2018 May;
13(5):e0196478.
PMID: 29734352
Background: The development of thrombocytopenia in sepsis is a poor prognostic indicator associated with a significantly increased mortality risk. Mechanisms underlying this phenomenon remain to be clearly elucidated. Matrix metalloproteinases...
7.
Larkin C, Breen E, Tomaszewski K, Eisele S, Radomski M, Ryan T, et al.
Platelets
. 2017 Nov;
29(3):301-304.
PMID: 29120698
Antiplatelet therapies remain an area of potential interest for the treatment of sepsis; however, studies of platelet aggregation in sepsis have yielded conflicting results. We examined platelet aggregation patterns in...
8.
Radziwon-Balicka A, Lesyk G, Back V, Fong T, Loredo-Calderon E, Dong B, et al.
Cardiovasc Res
. 2017 Oct;
113(14):1719-1731.
PMID: 29016749
Aims: In addition to maintaining haemostasis, circulating blood platelets are the cellular culprits that form occlusive thrombi in arteries and veins. Compared to blood leucocytes, which exist as functionally distinct...
9.
Larkin C, Santos-Martinez M, Ryan T, Radomski M
Thromb Res
. 2016 Mar;
141:11-6.
PMID: 26953822
No abstract available.
10.
Radomska A, Leszczyszyn J, Radomski M
Adv Clin Exp Med
. 2016 Mar;
25(1):151-62.
PMID: 26935510
The very dynamic growth of nanotechnology, nanomaterials (sized 1-100 nm) and their medical applications over the past 10 years has promised to add a new impetus to the diagnostics and...